By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Mary Jane's PostMary Jane's Post
  • Tech
  • Science
  • Culture & Arts
  • Press Releases
  • More
    • About Us
    • Advertise
    • Monthly Give-Away
    • Partner With Us
  • Join UsNew
Reading: Cannabis-Induced psychosis (CIP) Epidemiology Forecast Research Report 2022-2032 – ResearchAndMarkets.com
Share
0

No products in the cart.

Aa
Mary Jane's PostMary Jane's Post
Aa
  • Press Releases
  • Submit News
  • Join UsNew
Search
  • Topics
    • Business
    • Cannabis Community
    • Cannabis Tech
    • Culture & Arts
    • Industry Leaders
    • Press Releases
  • About Us
    • Guest Columnist
    • Ambassador
    • Partner With Us
Have an existing account? Sign In
Follow US
©2018 - 2022 TheRkive Entertainment Group, LLC. All Rights Reserved.
Mary Jane's Post > Press Releases > Cannabis-Induced psychosis (CIP) Epidemiology Forecast Research Report 2022-2032 – ResearchAndMarkets.com
Press Releases

Cannabis-Induced psychosis (CIP) Epidemiology Forecast Research Report 2022-2032 – ResearchAndMarkets.com

Business Wire
Posted Business Wire March 15, 2022
Updated 2022/03/15 at 5:32 PM
3 Min Read
SHARE

DUBLIN–(BUSINESS WIRE)–The “Cannabis-Induced psychosis (CIP) – Epidemiology Forecast – 2032” report has been added to ResearchAndMarkets.com’s offering.

logo Cannabis News

This “Cannabis-Induced psychosis (CIP) – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Cannabis-Induced psychosis (CIP) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Cannabis-Induced psychosis (CIP) Understanding

The Cannabis-Induced psychosis (CIP) epidemiology report gives a thorough understanding of the Cannabis-Induced psychosis (CIP) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Cannabis-Induced psychosis (CIP) in the US, Europe, and Japan. The report covers the detailed information of the Cannabis-Induced psychosis (CIP) epidemiology scenario in seven major countries (US, EU5, and Japan).

Cannabis-Induced psychosis (CIP) Epidemiology Perspective

The Cannabis-Induced psychosis (CIP) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Cannabis-Induced psychosis (CIP) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM.

The Cannabis-Induced psychosis (CIP) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Cannabis-Induced psychosis (CIP) Detailed Epidemiology Segmentation

The Cannabis-Induced psychosis (CIP) epidemiology covered in the report provides historical as well as forecasted Cannabis-Induced psychosis (CIP) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The Cannabis-Induced psychosis (CIP) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Report Highlights

  • 11-year Forecast of Cannabis-Induced psychosis (CIP) epidemiology
  • 7MM Coverage
  • Prevalent and Diagnosed Cases of Cannabis-Induced psychosis (CIP)
  • Cases of Cannabis-Induced psychosis (CIP) by Mutation Types
  • Cannabis-Induced psychosis (CIP) Cases associated with Clinical Manifestations

Key Assessments

  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Key Topics Covered:

1. Key Insights

2. Executive Summary of Cannabis-Induced psychosis (CIP)

3. Cannabis-Induced psychosis (CIP): Disease Background and Overview

3.1. Introduction

3.2. Sign and Symptoms

3.3. Pathophysiology

3.4. Risk Factors

3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 7MM

5.3. Epidemiology Scenario: 7MM

5.3.1. Cannabis-Induced psychosis (CIP) Epidemiology Scenario in the 7MM (2019-2032)

5.4. United States Epidemiology

5.4.1. Cannabis-Induced psychosis (CIP) Epidemiology Scenario in the United States (2019-2032)

5.5. EU-5 Country-wise Epidemiology

5.5.1. Germany Epidemiology

5.5.2. France Epidemiology

5.5.3. Italy Epidemiology

5.5.4. Spain Epidemiology

5.5.5. United Kingdom Epidemiology

5.6. Japan Epidemiology

6. Treatment Algorithm, Current Treatment, and Medical Practices

6.1. Cannabis-Induced psychosis (CIP) Treatment and Management

6.2. Cannabis-Induced psychosis (CIP) Treatment Algorithm

7. KOL Views

8. Unmet Needs

9. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/73t5zp

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

You Might Also Like

Heritage Cannabis Reports 2021 Year-End Financial Results

Flora Growth Launches Vessel in Canada; Signs Deal With Ontario Cannabis Store and Launches Vesselbrand.ca

Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2022 Financial Results and Recent Updates

Houston Area Army Veteran Reclaims Life, Eliminates Opioid Use with Medical Cannabis

Heritage Cannabis Announces Corporate Update and Highlights Significant Sales Growth, Market Share and Growing Distribution

TAGGED: Business Wire
Business Wire March 15, 2022
Share this Article
Facebook Twitter Pinterest LinkedIn Reddit
Share
Business Wire
Posted by Business Wire
Follow:
Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure. Investor relations, public relations, public policy, and marketing professionals rely on Business Wire for secure and accurate distribution of market-moving news and multimedia.
Previous Article Healthtech Company Veriheal Releases Gender-Focused Medical Cannabis Preference Report
Next Article Fentanyl – Not Just an Opioid Problem – Warns Caron Treatment Centers
- Advertisement -
Ad imageAd image

Stay Connected

Facebook Like
Twitter Follow
Pinterest Pin
Instagram Follow

You Might Also Like

Heritage Cannabis Reports 2021 Year-End Financial Results

May 12, 2022

Flora Growth Launches Vessel in Canada; Signs Deal With Ontario Cannabis Store and Launches Vesselbrand.ca

May 11, 2022

Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2022 Financial Results and Recent Updates

May 11, 2022

Houston Area Army Veteran Reclaims Life, Eliminates Opioid Use with Medical Cannabis

May 11, 2022
Mary Jane's PostMary Jane's Post

©2018 - 2022 TheRkive Entertainment Group, LLC. All Rights Reserved.

  • PRIVACY
  • TERMS OF USE
  • CONTRIBUTOR AGREEMENT
  • CONTRIBUTOR GUIDELINES

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Register Lost your password?